Michael Sherman, MD, MBA, MS
Venture Partner, RA Ventures
Dr. Michael Sherman serves as venture partner at RA Capital Management, a $10 billion multi-stage investment manager, dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. He also holds a faculty appointment in the Department of Population Medicine at Harvard Medical School. Prior to joining RA, Dr. Sherman served as executive vice president and chief medical officer at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan, two leading not-for-profit health plans insuring over 2 million members.
Prior to the merger, he served as chief medical officer of Harvard Pilgrim Health Care, nationally recognized for both innovation and quality, and he has been widely recognized as a pioneer in bringing advances in transformational therapeutics, precision medicine, and digital therapeutics to the market.
In 2018, he received Xconomy’s “Contrarian Award” for his contributions, including having signed the nation’s first such payment model for a gene therapy, helping pave the way for developing innovative financing models. Dr. Sherman’s work is also featured in a Harvard Business School case study published in 2021.
Dr. Sherman holds board appointments with several well-respected nonprofit organizations, including the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, and NEHI (Network for Excellence in Health Innovation). Dr, Sherman has also served on the advisory board of the Institute for Clinical and Economic Review (ICER), the board of overseers of Boston’s internationally renowned Museum of Science, and the Massachusetts Rare Disease Advisory Council.
Before pursuing an M.B.A. at Harvard Business School, Dr. Sherman received his M.D. from Yale and practiced as a cardiac anesthesiologist. He also holds a B.A. in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania.